摘要
目的:基于TOPSIS法综合评价补肾活血方不同极性部位对糖尿病视网膜病变(DR)的治疗作用。方法:依次用石油醚、三氯甲烷、乙酸乙酯、正丁醇和水提取补肾活血方得到不同极性部位提取物。比较不同极性部位给药后大鼠视网膜消化铺片,免疫组化法检测VEGF和HIF-1α的蛋白表达,ELISA法测定血浆AGEs浓度,采用TOPSIS法综合评价不同极性部位对DR的治疗作用。结果:与空白组比较,模型组各检测结果均具有显著性差异;与模型组比较,各给药组对DR大鼠视网膜微血管内皮细胞与周细胞比值明显降低,血浆AGEs浓度明显降低,视网膜VEGF、HIF-1α蛋白表达下调。TOPSIS法综合评价结果显示各不同极性部位给药组得分按高低排序为三氯甲烷组>正丁醇组>石油醚组>乙酸乙酯组>水部位组,表明三氯甲烷部位对DR改善效果最佳,水部位效果最差。结论:补肾活血方不同极性部位对DR有不同程度的改善作用,其中三氯甲烷部位对DR治疗效果最优;基于TOPSIS法可公正、客观地评价补肾活血方不同极性部位治疗DR的药效作用。
Objective:To evaluate the therapeutic effects of different polar parts from Bushen Huoxue prescription on diabetic retinopathy(DR)based on TOPSIS.Methods:The extracts of different polar parts were obtained by successively extracting Bushen Huoxue prescription with petroleum ether,chloroform,ethyl acetate,n-butanol and water.Retinas after administration with different polar parts were compared and prepared,expressions of VEGF and HIF-1αprotein were determined by immunohistochemisty,AGEs concentration in plasma was determined by ELISA.The therapeutic effects of different polar parts on DR were evaluated based on TOPSIS.Results:Compared with the control group,the pharmacological test results in all model groups showed significantly difference.Compared with the model group,the ratios of microvascular endothelial cell to peripheral cells were decreased in all different polar parts groups,AGEs concentration was decreased,protein expressions of VEGF and HIF-1αwere down regulated.TOPSIS evaluation showed that the scores in each group were ranks as chloroform group>n-butanol group>petroleum ether group>ethyl acetate group>water part group,indicating that the chloroform part had the best improvement effect on DR while the effect of water part was the worst.Conclusion:The different polar parts from Bushen Huoxue prescription have different effects on DR.Among them,the chloroform part is the best for treating DR.Based on TOPSIS method,the effect of different polar parts from Bushen Huoxue prescription on DR can be evaluated fairly and objectively.
作者
王芯
邓立萍
谢孟君
张梅
谢学军
Wang Xin;Deng Liping;Xie Mengjun;Zhang Mei**;Xie Xuejun(School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137;Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2019年第4期154-160,共7页
Pharmacology and Clinics of Chinese Materia Medica
基金
国家自然科学基金资助项目(81774202)
四川省科技厅应用基础研究重点项目(2017JY0013)
